Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences


Theoretical and Natural Science

Vol. 29, 16 January 2024

Open Access | Article

Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook

Letao Lu * 1 , Sishuo Ye 2
1 Guangzhou No.16 Middle School
2 Chongqing Depu Foreign Language School

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 29, 25-36
Published 16 January 2024. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Letao Lu, Sishuo Ye. Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook. TNS (2024) Vol. 29: 25-36. DOI: 10.54254/2753-8818/29/20240643.

Abstract

In the US, hepatocellular carcinoma (HCC), which accounts for 75%–85% of instances of liver cancer, is a substantial cause of cancer-related fatalities. This review focuses on the recent developments in managing HCC, specifically through Trans-arterial Chemoembolization (TACE), which is currently first-line recommended and boasts a high survival rate. We have also discussed gene therapy, which aims to correct or replace faulty genes contributing to HCC development. Although it is still on trial, early results show promise. There are also various treatments such as OLT, molecularly targeted therapy, radiation therapy, locoregional therapies, gene therapy and immunotherapy. We have also come up with an innovative idea of creating a therapeutic vaccine using circRNA instead of mRNA, along with LNP, to treat HCC. This approach combines the benefits and functions of both circRNA and LNP. Different components of LNP aid in diverse benefits, to name but a few, stability, encapsulation and delivery efficiency, and higher targeting specificity. The use of circRNA offers adjuvant to immune response and better stability. Recent studies suggest that this hypothesis is theoretically possible. A better understanding of the hazardous disease could lead to the development of more effective treatments, which are urgently needed.

Keywords

Hepatocellular Carcinoma (HCC), TACE, chemotherapy, immunotherapy, LNP-circRNA therapeutic vaccine

References

1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018

2. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87:227–247

3. Yi SW, Choi JS, Yi JJ, Lee YH, Han KJ. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea. Cancer. 2018 Jul 1;124(13):2748-2757. doi: 10.1002/cncr.31406. Epub 2018 Apr 18. PMID: 29669170

4. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32‐ii40. doi: 10.1136/ thx.2010.136994

5. Yuk Ho Liu, Eugene Yee Juen Lo, Kit Fai Lee, Charing Ching Ning Chong, Paul Bo San Lai, An unusual cause of upper gastrointestinal bleeding due to recurrent hepatocellular carcinoma: A case report, International Journal of Surgery Case Reports, Volume 70, 2020, Pages 83-86, ISSN 2210-2612

6. Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004). Randomized controlled trial of screening for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 130(7). https://doi.org/10.1007/s00432-004-0552-0

7. Pal Chaudhary Surendra,Reyes Stephanie,Chase Matthew L,Govindan Aparna,Zhao Lei,Luther Jay,Bhan Irun,Bethea Emily,Franses Joseph W,Paige Walsh Elizabeth,Anne Dageford Leigh,Kimura Shoko,Elias Nahel,Yeh Heidi,Markman James,Bozorgzadeh Adel,Tanabe Kenneth,Ferrone Cristina,Zhu Andrew X,Andersson Karin,Thiim Michael,Antonio Catalano Onofrio,Kambadakone Avinash,Vagefi Parsia A,Qadan Motaz,Pratt Daniel,Hashemi Nikroo,Corey Kathleen E,Misdraji Joseph,Goyal Lipika,Clark Jeffrey W. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.[J]. The oncologist,2023.

8. Hu Yue,Li Zheng,Jiang Yunlan,Wang Xin,He Weilan. Letter to the Editor: More efforts for the meta-analysis of the association between hepatic steatosis and HBV-related HCC.[J]. Hepatology (Baltimore, Md.),2023.

9. Chan Landon L.,Chan Stephen L.. The combination of ALBI and AFP response: A small step forward in HCC[J]. Liver International,2023,43(2).

10. Badgujar L,Singh P,Ademisoye E,Kim I,Ifeanyichi M,Nientker L. EE579 Economic and Humanistic Evidence in Early-Stage Hepatocellular Carcinoma (HCC) Post Liver Resection or Ablation – A Systematic Literature Review (SLR)[J]. Value in Health,2022,25(12S).

11. Bettinelli Andrea,Marturano Francesca,Ballo Mattia,Billato Ilaria,Cabrelle Giulio,Carandina Riccardo,Crimì Filippo,Lupi Amalia,Paiusco Marta,Pizzirani Enrico,Ricciardi Costantino,Cillo Umberto. 340 - STABILITY OF RADIOMIC FEATURES TO MULTIPLE-READER SEGMENTATIONS IN CONTRAST-ENHANCED COMPUTED TOMOGRAPHY (CECT) IMAGES OF HEPATOCELLULAR CARCINOMA (HCC)[J]. Physica Medica,2022,104(S1).

12. Jaffe Ariel,Taddei Tamar H,Giannini Edoardo G,IlaganYing Ysabel C,Colombo Massimo,Strazzabosco Mario. Alternative HCC Prognostic Biomarkers and Use of Artificial Intelligence in Management of HCC. [J]. Liver international : official journal of the International Association for the Study of the Liver,2022.

13. Xu Qiuran,Dou Changwei,Liu Xin,Yang Liu,Ni Chao,Wang Jiahui,Guo Yang,Yang Wei,Tong Xiangmin,Huang Dongsheng. Corrigendum to “Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis” [Biomed. Pharmacother. 107 (2018) 1692-1704].[J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2022,157.

14. Zeidan Elie,Beaudoin Annie. S1243 Epidemiology of Hepatocellular Carcinoma (HCC) in a Canadian University Centre[J]. The American Journal of Gastroenterology,2022,117(10S).

15. Civan Jesse. S3008 HCC Recurrence Post Liver Transplant With Rapid Progression in a Patient Presenting With Elevated Transaminases[J]. The American Journal of Gastroenterology,2022,117(10S).

16. Li Shaling,Hu Xingwang,Yu Songman,Yi Panpan,Chen Ruochan,Huang Zebing,Huang Yan,Huang Yun,Zhou Rongrong,Fan Xuegong. Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.[J]. Cancer science,2022,114(2).

17. Xiao Yuyao,Zheng Xinde,Zhou Changwu,Huang Peng,Wu Fei,Yang Chun,Zeng Mengsu. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.[J]. European radiology,2022,33(2).

18. Kim JW, Kim JH, Sung KB, Ko HK, Shin JH, Kim PN, Choi HK, Ko GY, Yoon HK, Chun SY, Gwon DI. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Am J Gastroenterol. 2014 Aug;109(8):1234-40. doi: 10.1038/ajg.2014.152. Epub 2014 Jun 17. PMID: 24935276.

19. Tsurusaki M., Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer. 2015;4:165–175. doi: 10.1159/000367739.

20. Zou J.H., Zhang L., Ren Z.G., Ye S.L. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: A meta- analysis. J. Dig. Dis. 2016;17:510–517. doi: 10.1111/1751-2980.12380.

21. Tsurusaki M., Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer. 2015;4:165–175. doi: 10.1159/000367739.

22. Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Corti A, Tredici M, Piccinno M, Giorgi L, Bartolozzi C, Bargellini I. Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol. 2015 Jun 7;21(21):6518-25. doi: 10.3748/wjg.v21.i21.6518. PMID: 26074690; PMCID: PMC4458762.

23. Cong Y, Sun B, Wang J, Meng X, Xuan L, Zhang J, Liu J, Shen G, Wu S. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer. Thorac Cancer. 2019 Jul;10(7):1567-1575. doi: 10.1111/1759-7714.13105. Epub 2019 Jun 11. PMID: 31187604; PMCID: PMC6610283.

24. Sun Na,Zhang Ceng,Lee YiTe,Tran Benjamin V,Wang Jing,Kim Hyoyong,Lee Junseok,Zhang Ryan Y,Wang Jasmine J,Hu Junhui,Zhang Zhicheng,Alsudaney Manaf S,Hou KuanChu,Tang Hubert,Zhang Tiffany X,Liang Icy Y,Zhou Ziang,Chen Mengxiang,Yeh Angela HsiaoJiun,Li Wenyuan,Zhou Xianghong Jasmine,Chang Helena R,Han StevenHuy B,Sadeghi Saeed,Finn Richard S,Saab Sammy,Busuttil Ronald W,Noureddin Mazen,Ayoub Walid S,Kuo Alexander,Sundaram Vinay,AlGhaieb Buraq,Palomique Juvelyn,Kosari Kambiz,Kim Irene K,Todo Tsuyoshi,Nissen Nicholas N,Tomasi Maria Lauda,You Sungyong,Posadas Edwin M,Wu James,Wadehra Madhuri,Sim MyungShin,Li Yunfeng,Wang Hanlin,French Samuel W,Lu Shelly C,Wu Lily,Pei Renjun,Liang Li,Yang Ju Dong,Agopian Vatche G,Tseng HsianRong,Zhu Yazhen. HCC EV ECG Score: An Extracellular Vesicle-based Protein Assay for Detection of Early-Stage Hepatocellular Carcinoma.[J]. Hepatology (Baltimore, Md.),2022,77(3).

25. Mandorfer Mattias. Individualization of HCC and Portal Hypertension Surveillance in Patients with Compensated Advanced Chronic Liver Disease and SVR.[J]. Digestive diseases and sciences,2022,68(1).

26. Soulette Cameron,May Lindsey,Khakpoor Atefeh,Han Dong,Ramirez Ricardo,Balakrishnan Narmada,Van Buuren Nicholas,Dasgupta Ramanuj,Suri Vithika,Li Li,Mo Hongmei,Feierbach Becket,Wallin Jeffrey,Lim Seng Gee. THU308 - Long-read sequencing of HCC samples reveals complete architecture of HBV integrations and chimeric mRNA isoforms associated with oncogenes[J]. Journal of Hepatology,2022,77(S1).

27. Dasu Neethi R.,Khalid Yaser,Suga Herman,Chhoun Christopher K.,Foster C Jonathan. Sa1414: TRENDS OF HEPATOCELLULAR CARCINOMA (HCC) PREVALENCE AND MORTALITY FROM 2005-2019[J]. Gastroenterology,2022,162(7S).

28. M Grierson Patrick,Park Haeseong. Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC.[J]. JCO oncology practice,2021,18(1).

29. Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG. RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. Mol Cell. 2019 May 2;74(3):508-520.e4. doi: 10.1016/ j.molcel.2019.02.015. Epub 2019 Mar 19. PMID: 30902547; PMCID: PMC6724735.

30. Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, Li Y, Huang W. Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics. 2022 Dec 1;14(12):2682. doi: 10.3390/pharmaceutics14122682. PMID: 36559175; PMCID: PMC9787894.

31. Camilla Hald Albertsen, Jayesh A. Kulkarni, Dominik Witzigmann, Marianne Lind, Karsten Petersson, Jens B. Simonsen, The role of lipid components in lipid nanoparticles for vaccines and gene therapy, Advanced Drug Delivery Reviews, Volume 188,2022,114416, ISSN 0169-409X,https://doi.org/10.1016/j.addr.2022.114416.

32. Kim M, Jeong M, Hur S, Cho Y, Park J, Jung H, Seo Y, Woo HA, Nam KT, Lee K, Lee H. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci Adv. 2021 Feb 26;7(9):eabf4398. doi: 10.1126/sciadv.abf4398. PMID: 33637537; PMCID: PMC7909888.

33. Steffens, R.C., Wagner, E. Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery. Pharm Res 40, 47–76 (2023). https://doi.org/10.1007/s11095-022-03385-w

34. Liu S, Cheng Q, Wei T, Yu X, Johnson LT, Farbiak L, Siegwart DJ. Membrane- destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater. 2021 May;20(5):701-710. doi: 10.1038/s41563-020-00886-0. Epub 2021 Feb 4. PMID: 33542471; PMCID: PMC8188687.

35. Jiao S, Wu S, Huang S, Liu M, Gao B. Advances in the Identification of Circular RNAs and Research Into circRNAs in Human Diseases. Front Genet. 2021 Mar 19;12:665233. doi: 10.3389/ fgene.2021.665233. PMID: 33815488; PMCID: PMC8017306.

36. Ipshita Menon, Maryam Zaroudi, Yuanzhe Zhang, Elizabeth Aisenbrey, Liwei Hui, Fabrication of active targeting lipid nanoparticles: Challenges and perspectives, Materials Today Advances, Volume 16,2022,100299, ISSN 2590-0498, https://doi.org/10.1016/ j.mtadv.2022.100299.

37. Y Yarden, The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities, European Journal of Cancer, Volume 37, Supplement 4, 2001, Pages 3-8, ISSN 0959-8049, https://doi.org/10.1016/ S0959-8049(01)00230-1.

38. Jeong TJ, Lee HT, Gu N, Jang YJ, Choi SB, Park UB, Lee SH, Heo YS. The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines. 2022 Dec 6;10(12):3154. doi: 10.3390/biomedicines10123154. PMID: 36551910; PMCID: PMC9775377.

39. Deng Z, Tian Y, Song J, An G, Yang P. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Front Immunol. 2022 Jun 2;13:887125. doi: 10.3389/fimmu.2022.887125. PMID: 35720301; PMCID: PMC9201022.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 2nd International Conference on Modern Medicine and Global Health
ISBN (Print)
978-1-83558-279-4
ISBN (Online)
978-1-83558-280-0
Published Date
16 January 2024
Series
Theoretical and Natural Science
ISSN (Print)
2753-8818
ISSN (Online)
2753-8826
DOI
10.54254/2753-8818/29/20240643
Copyright
16 January 2024
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated